ReviewBreast cancer research : BCR2009
Recent advances in systemic therapy: new diagnostics and biological predictors of outcome in early breast cancer.
Review in Breast cancer research : BCR, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed.
- The impact of Oncotype DX testing on breast cancer management and chemotherapy prescribing patterns in a tertiary referral centre.European journal of cancer (Oxford, England : 1990) · 2014Trial
- Correlation of microarray-based breast cancer molecular subtypes and clinical outcomes: implications for treatment optimization.BMC cancer · 2011Trial
- ¹⁸F-FDG PET and biomarkers for tumour angiogenesis in early breast cancer.European journal of nuclear medicine and molecular imaging · 2011Trial
- Lymphovascular invasion in hormone-positive, human epidermal growth factor-negative, low-burden axillary disease in early breast cancer patients tested for oncotype DX recurrence score.Contemporary oncology (Poznan, Poland) · 2022Article
- How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients.Current oncology (Toronto, Ont.) · 2021Article
- Copy number profiling of Oncotype DX genes reveals association with survival of breast cancer patients.Molecular biology reports · 2018Article
- Estimating Breast Cancer Survival by Molecular Subtype in the Absence of Screening and Adjuvant Treatment.Medical decision making : an international journal of the Society for Medical Decision Making · 2018Article
- Gene expression assay and Watson for Oncology for optimization of treatment in ER-positive, HER2-negative breast cancer.PloS one · 2018Article
- Polyphenols as Promising Drugs against Main Breast Cancer Signatures.Antioxidants (Basel, Switzerland) · 2017Review
- Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer.Breast cancer (Dove Medical Press) · 2017Review
- 4-IHC classification of breast cancer subtypes in a large cohort of a clinical cancer registry: use in clinical routine for therapeutic decisions and its effect on survival.Breast cancer research and treatment · 2015Article
- Effects of screening and systemic adjuvant therapy on ER-specific US breast cancer mortality.Journal of the National Cancer Institute · 2014Article
- Chromatin CKAP2, a new proliferation marker, as independent prognostic indicator in breast cancer.PloS one · 2014Article
- Evaluation and correlation of risk recurrence in early breast cancer assessed by Oncotype DXMolecular and clinical oncology · 2013Article
- Ki-67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry.Breast cancer research and treatment · 2013Article
- Comparison of EndoPredict and Oncotype DX test results in hormone receptor positive invasive breast cancer.PloS one · 2013Article
- Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype.BMC research notes · 2012Article
- Improving communication of breast cancer recurrence risk.Breast cancer research and treatment · 2012Article
- [Assessment of proliferation: core biopsy or resection specimen? Discrepancies in breast cancer with low and high proliferation].Der Pathologe · 2012Review
- Ki-67: level of evidence and methodological considerations for its role in the clinical management of breast cancer: analytical and critical review.Breast cancer research and treatment · 2012Review
Corrections and comments
- Commented on by
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The key to optimising our approach in early breast cancer is to individualise care. Each patient has a tumour with innate features that dictate their chance of relapse and their responsiveness to treatment. Often patients with similar clinical and pathological tumours will have markedly different outcomes and responses to adjuvant intervention. These differences are encoded in the tumour genetic profile. Effective biomarkers may replace or complement traditional clinical and histopathological markers in assessing tumour behaviour and risk. Development of high-throughput genomic technologies is enabling the study of gene expression profiles of tumours. Genomic fingerprints may refine prediction of the course of disease and response to adjuvant interventions. This review will focus on the role of multiparameter gene expression analyses in early breast cancer, with regards to prognosis and prediction. The prognostic role of genomic signatures, particularly the Mammaprint and Rotterdam signatures, is evolving. With regard to prediction of outcome, the Oncotype Dx multigene assay is in clinical use in tamoxifen treated patients. Extensive research continues on predictive gene identification for specific chemotherapeutic agents, particularly the anthracyclines, taxanes and alkylating agents.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.